Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
In a poster presented at APA, researchers review current clinical practice guidelines for schizophrenia.
An overview of clinical guidelines show AP monotherapy is the treatment of choice for patients with a first schizophrenia episode.
In a poster presented at the American Psychiatric Association Virtual Meeting, a research team led by Christoph Correll, MD, professor of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, conducted a literature review of current schizophrenia guidelines.
The researchers found all available guidelines stated that a different single antipsychotic should be tried if the first is ineffective or intolerable, but there was less consensus on maintenance therapy, likely based on insufficient longer-term data and conflicting results in current meta-analyses.
The recommendations on duration of antipsychotic therapy after a first schizophrenia episode varied across the different clinical practice guidelines.
In an interview with HCPLive®, Correll explained how the COVID-19 pandemic might influence schizophrenia care and how difficult it is to craft guidelines for a disease with a wide range of symptoms, with treatments that could have a wide range of side effects.
Correll also said the process for updating clinical practice guidelines should change, allowing for a quicker revision process when new studies are conducted, or new treatments are developed.